Mesenchymal stem cells (MSC) can differentiate into osteoblasts, adipocytes, chondrocytes and myoblasts. It has been suggested that a reciprocal relationship exists between the differentiation of MSC into osteoblasts and adipocytes. Peroxisome proliferator-activated receptor γ2 (PPARγ2) is a key element for the differentiation into adipocytes. Activation of the nuclear protein deacetylase Sirt1 has recently been shown to decrease adipocyte development from preadipocytes via inhibition of PPARγ2. In vitro, MSC differentiate to osteoblasts when exposed to bone-inducing medium. However, adipocytes are also developed. In the present study we have targeted Sirt1 to control adipocyte development during differentiation of MSC into osteoblasts. The finding that resveratrol and isonicotinamide markedly inhibited adipocyte and promoted osteoblast differentiation demonstrates an interesting alternative to PPARγ antagonists. These results are important for the evolving field of cell-based tissue engineering, but may also be relevant in the search for new treatments of osteoporosis.

Keywords:
Sirt1, PPARγ, Mesenchymal stem cells, Osteoblast, Adipocyte
1.
Akune, T., S. Ohba, S. Kamekura, M. Yamaguchi, U.I. Chung, N. Kubota, Y. Terauchi, Y. Harada, Y. Azuma, K. Nakamura, T. Kadowaki, H. Kawaguchi (2004) PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113: 846–855.
2.
Bäckesjö, C.M., Y. Li, U. Lindgren, L.A. Haldosén (2006) Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res 21: 993–1002.
3.
Burkhardt, R., G. Kettner, W. Bohm, M. Schmidmeier, R. Schlag, B. Frisch, B. Mallmann, W. Eisenmenger, T. Gilg (1987) Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone 8: 157–164.
4.
Hihi, A.K., L. Michalik, W. Wahli (2002) PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 59: 790–798.
5.
Lecka-Czernik, B., E.J. Moerman, D.F. Grant, J.M. Lehmann, S.C. Manolagas, R.L. Jilka (2002) Divergent effects of selective peroxisome proliferator-activated receptor-γ 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143: 2376–2384.
6.
Meunier, P., J. Aaron, C. Edouard, G. Vignon (1971) Osteoporosis and the replacement of cell populations of the marrow by adipose tissue: a quantitative study of 84 iliac bone biopsies. Clin Orthop 80: 147–154.
7.
Picard, F., M. Kurtev, N. Chung, A. Topark- Ngarm, T. Senawong, R. Machado De Oliveira, M. Leid, M.W. McBurney, L. Guarente (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature 429: 771–776.
8.
Porcu, M., A. Chiarugi (2005) The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci 26: 94–103.
9.
Ren, D., T.N. Collingwood, E.J. Rebar, A.P. Wolffe, H.S. Camp (2002) PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis. Genes Dev 16: 27–32.
10.
Rzonca, S.O., L.J. Suva, D. Gaddy, D.C. Montague, B. Lecka-Czernik (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401–406.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.